Antibody-mediated rejection

Bortezomib-based treatment of acute antibody-mediated rejection: a case report

Q. Wang, Li, X. L., Xu, X. G., Shi, B. Y., Zhang, Z. M., Li, Z. L., Han, Y., Zhou, W. Q., Chen, C. Q., Cai, M., and Zhang, X., Bortezomib-based treatment of acute antibody-mediated rejection: a case report, vol. 14, pp. 17951-17958, 2015.

Antibody-mediated rejection (AMR) is an important factor affecting survival after renal transplantation. A highly selective proteasome inhibitor, bortezomib, clears activated plasma cells from the body and has important therapeutic effect on AMR. We investigated the effects of bortezomib on AMR in a patient after a second renal transplant. Biopsy confirmed the diagnosis of mixed cellular rejection and AMR. Bortezomib was administered on day 1 (1.3 mg/m2), day 4 (1.0 mg/m2), and day 8 (1.0 mg/m2).

Subscribe to Antibody-mediated rejection